Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Urcosimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    OKYO Pharma Announces Chairman And Founder Acquires Shares
    OKYO Pharma Announces Chairman And Founder Acquires Shares

    21 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/21/3192792/0/en/OKYO-Pharma-Announces-Chairman-and-Founder-Acquires-Shares.html

    GLOBENEWSWIRE
    21 Nov 2025
    Share Share
    OKYO Pharma To Present At OIS XV In San Diego
    OKYO Pharma To Present At OIS XV In San Diego

    18 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/18/3190029/0/en/OKYO-Pharma-to-Present-at-OIS-XV-in-San-Diego.html

    GLOBENEWSWIRE
    18 Nov 2025
    Share Share
    Okoyo Pharma Initiates 100-Patient Trial For Urcosimod
    Okoyo Pharma Initiates 100-Patient Trial For Urcosimod

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153922/0/en/OKYO-Pharma-Announces-Registration-Pathway-with-100-Patient-Multi-Center-Clinical-Trial-of-Urcosimod-in-Neuropathic-Corneal-Pain.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    OKYO Pharma's Phase 2 Results for Urcosimod in Corneal Pain
    OKYO Pharma's Phase 2 Results for Urcosimod in Corneal Pain

    16 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/16/3116513/0/en/OKYO-Pharma-Unveils-Strong-Phase-2-Clinical-Trial-Results-for-Urcosimod-to-Treat-Neuropathic-Corneal-Pain.html

    GLOBENEWSWIRE
    16 Jul 2025
    Share Share
    FDA Grants OKYO Fast Track for Urcosimod Neuropathic Corneal Pain
    FDA Grants OKYO Fast Track for Urcosimod Neuropathic Corneal Pain

    01 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/01/3072233/0/en/FDA-Grants-OKYO-Pharma-Fast-Track-Designation-to-Urcosimod-for-Neuropathic-Corneal-Pain.html

    GLOBENEWSWIRE
    01 May 2025
    Share Share